Volume 76, Issue 1 pp. 55-57
Full Access

CA-antibody: an immunological marker of thymic neoplasia in myasthenia gravis?

J.A. Aarli

Corresponding Author

J.A. Aarli

Department of Neurology, Haukeland Hospital, and Broegelmann Research Laboratory for Microbiology, University of Bergen, Norway

*Johan A. Aarli, Neurology Department 5016 Haukeland Hospital NorwaySearch for more papers by this author
N.E. Gilhus

N.E. Gilhus

Department of Neurology, Haukeland Hospital, and Broegelmann Research Laboratory for Microbiology, University of Bergen, Norway

Search for more papers by this author
H. Hofstad

H. Hofstad

Department of Neurology, Haukeland Hospital, and Broegelmann Research Laboratory for Microbiology, University of Bergen, Norway

Search for more papers by this author
First published: July 1987
Citations: 16

Abstract

Abstract We have examined sera from 141 patients with myasthenia gravis and 11 non-myasthenia gravis patients with thymoma for antibodies to a citric acid extract of skeletal muscle (CA-antibodies). Sera were obtained from 5 different centers. The thymus histology was defined in each case. Sera from 56/66 patients (85%) with thymoma contained CA-antibodies, while such antibodies were only detected in 6/75 (8%) of the non-thymoma patients. None of the patients with thymus hyperplasia had CA-antibodies. One MG patient who developed MG after a bone-marrow transplantation, also developed CA-antibodies. The remaining 5 CA positive non-thymoma MG patients were all >65 years and had thymic atrophy. Two of them had myasthenia gravis and polymyalgia rheumatica. In 2 thymoma patients with non-detectable levels of CA-antibodies before thymectomy, such antibodies were demonstrated in high titres after the operation. In 2 other sera from thymoma patients, the titres of CA-antibodies fell to <32 after thymectomy. There were 3 sera with CA-antibodies among 11 sera from non-MG patients with thymic tumours.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.